Navigation Links
Drugs.com Releases Q2 Sales for Top 100 U.S. Prescription Drugs: Humira Climbs into Top 5 and Posts Double-Digit Growth
Date:8/14/2013

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2013 U.S. prescription sales data for the top 100 drugs. Since Q2 2012, Otuska's antipsychotic Abilify and AstraZeneca's acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each posts close to $1.5 billion in sales. Humira, AbbVie's key tumor necrosis factor (TNF) blocker, climbs three notches and sees a double-digit gain for the quarter.

(Photo: http://photos.prnewswire.com/prnh/20130814/PH63256-a )
(Photo: http://photos.prnewswire.com/prnh/20130814/PH63256-b )

Top Five Drugs by Sales, Q2 2013Drug NameSales ($000)% Change (previousquarter)Abilify

$1,597,913

+4.70%Nexium

$1,454,048

-0.34%Humira

$1,341,759

+10.22%Cymbalta

$1,338,912

+3.24%Crestor

$1,290,913

-0.37%The move of Humira into the top five shifts both Eli Lilly's Cymbalta, and AstraZeneca's Crestor down one position. Cymbalta, which reaped over $4.4 billion in 2012 U.S. sales, goes off patent this December.

Top Five Sales Gains, Q2 2013Drug NameGain ($000)% Change (previousquarter)Humira

$124,407

+10.22%doxycycline

$89,309

+46.22%Enbrel

$72,681

+6.76%Abilify

$71,685

+4.70%Epogen

$47,324

+9.40%Not only does Humira re-enter the top five drugs by sales, it also comes in at the number one spot in terms of sales growth. Enbrel, another TNF blocker, returns to positive growth after a slight drop in Q1. Abilify and Epogen round out the fourth and fifth spots in quarterly sales gains.

"The significant impact of TNF blockers on autoimmune disease activity is not only reflected in their varied indications such as rheumatoid arthritis, psoriasis and Crohn's disease, but also in their steady sales growth," said Philip Thornton, CEO of Drugs.com. "Since the second quarter of 2012, Humira, Enbrel, and Remicade have all placed in the top ten with revenues in the $1 billion range."

Top Five Sales Losses, Q2 2013 Drug NameLoss ($000)% Change (previousquarter)Avonex Pen

-$154,859

-45.78%Suboxone

-$78,819

-18.95%Advair Diskus

-$35,740

-2.80%Avonex

-$32,162

-9.51%modafinil

-$31,418

-14.37%Newer oral multiple sclerosis (MS) agents such as Novartis' Gilenya may now be impacting the use of injectable interferon such as Biogen Idec's Avonex, which loses significant growth this quarter. However, the news may not be all bad -- Biogen Idec also manufactures Tecfidera, the newest oral MS drug -- predicted to draw in over $3.5 billion in annual sales by 2017. Modafinil lost over 17 percent in sales gains in Q1 2013, and continues to slide this quarter.

Reckitt Benckiser's Suboxone for opiate dependence, now available only in the oral dissolvable film, drops close to $79 million. The sublingual tablet formulation of Suboxone, discontinued in March, can now be replaced with the generic version approved in February.

Detailed data on the top 100 drugs can be accessed at: http://www.drugs.com/stats/top100/sales

About Drugs.com
Drugs.com is the leading online drug information resource with over nine million unique visitors per month (ComScore, June 2013). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: http://www.drugs.com/

Media Inquiries:
Drugs.com Press Officer
Email
(718) 395 2473

Read more news from Drugs.com.

 


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu
2. Drugs.com Launches iOS and Android Mobile App to Empower Patients and Providers Alike
3. Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs
4. Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
5. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
6. Raritan Releases Dynamic Search User Interface on Amazon Web Services (AWS) Marketplace
7. Nutrastar Releases Second Quarter 2013 Results
8. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
9. Bekers Hospital Review Releases Report on State of Hospital Industry
10. Beckers Healthcare Releases Report on State of ASC Industry
11. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):